JP2011513414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513414A5 JP2011513414A5 JP2010549775A JP2010549775A JP2011513414A5 JP 2011513414 A5 JP2011513414 A5 JP 2011513414A5 JP 2010549775 A JP2010549775 A JP 2010549775A JP 2010549775 A JP2010549775 A JP 2010549775A JP 2011513414 A5 JP2011513414 A5 JP 2011513414A5
- Authority
- JP
- Japan
- Prior art keywords
- following structure
- compound
- substituted
- prodrug
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Claims (10)
- 下記の構造を有する化合物、またはその製薬上許容し得る塩、またはそのプロドラッグ:
(式中、Yは、下記:
であり;
Aは、‐(CH2)6‐、シス‐CH2CH=CH‐(CH2)3‐、または‐CH2C≡C‐(CH2)3‐であり、これらにおいて、1個または2個の炭素原子はSまたはOによって置換されていてもよく;或いは、Aは、‐(CH2)m‐Ar‐(CH2)o‐であり、Arはインターアリーレンまたはヘテロインターアリーレンであり、mとoの和は1、2、3または4であり、1個のCH2はSまたはOによって置換されていてもよく;
Jは、C=O、CHOH、CHF、CHCl、CHBrまたはCHCNであり;そして、
Bは、置換アリールまたは置換ヘテロアリールである)。 - Bが、置換フェニルである、請求項1記載の化合物。
- 脱毛症の治療用組成物を製造するための、請求項1〜9いずれか1項記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3486608P | 2008-03-07 | 2008-03-07 | |
US12/394,647 US7964596B2 (en) | 2008-03-07 | 2009-02-27 | Therapeutic compounds |
PCT/US2009/035656 WO2009114307A1 (en) | 2008-03-07 | 2009-03-02 | Therapeutic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011513414A JP2011513414A (ja) | 2011-04-28 |
JP2011513414A5 true JP2011513414A5 (ja) | 2012-04-19 |
Family
ID=41054305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010549775A Ceased JP2011513414A (ja) | 2008-03-07 | 2009-03-02 | 治療用化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7964596B2 (ja) |
EP (1) | EP2257548B1 (ja) |
JP (1) | JP2011513414A (ja) |
AU (1) | AU2009223435B9 (ja) |
BR (1) | BRPI0910251A2 (ja) |
CA (1) | CA2717632A1 (ja) |
DK (1) | DK2257548T3 (ja) |
ES (1) | ES2399009T3 (ja) |
WO (1) | WO2009114307A1 (ja) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
JP2529095B2 (ja) * | 1988-05-11 | 1996-08-28 | 株式会社上野製薬応用研究所 | 13,14−ジヒドロ−15−ケト−16−デスブチル−16−トリフルオロメチルフェノキシ−プロスタグランジンe2 |
US5476872A (en) * | 1993-10-18 | 1995-12-19 | Allergan, Inc. | 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1 |
US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
JP3183650B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | プロスタグランジン化合物 |
US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
US5698598A (en) * | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
DE69823852T2 (de) * | 1997-02-04 | 2005-05-19 | Johnstone, Murray A., Seattle | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
US6090847A (en) * | 1997-11-21 | 2000-07-18 | Allergan Sales, Inc. | EP2 -receptor agonists as neuroprotective agents for the eye |
US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
WO2000056711A1 (en) * | 1999-03-23 | 2000-09-28 | Sumitomo Pharmaceuticals Co., Ltd. | Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
MXPA02004646A (es) * | 1999-11-11 | 2002-09-02 | Lilly Co Eli | Antagonistas de leucotrieno de difenilo substituido con heterociclo. |
AU2001229252A1 (en) * | 2000-03-09 | 2001-09-17 | Eli Lilly And Company | Method for the treatment of renal dysfunction with spla2 inhibitors |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
CA2466517A1 (en) * | 2001-11-05 | 2003-05-15 | Allergan, Inc. | .omega.-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
IL162602A0 (en) * | 2001-12-20 | 2005-11-20 | Applied Research Systems | Pyrrolidine derivatives as prostaglandin modulators |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
TWI348386B (en) * | 2003-08-12 | 2011-09-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
US7547727B2 (en) | 2006-05-22 | 2009-06-16 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
US7498447B2 (en) * | 2006-05-24 | 2009-03-03 | Allergan, Inc. | Therapeutic compounds |
US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
AU2007261034B2 (en) | 2006-06-20 | 2012-09-13 | Allergan, Inc. | Therapeutic compounds |
-
2009
- 2009-02-27 US US12/394,647 patent/US7964596B2/en active Active
- 2009-03-02 WO PCT/US2009/035656 patent/WO2009114307A1/en active Application Filing
- 2009-03-02 EP EP09721183A patent/EP2257548B1/en not_active Not-in-force
- 2009-03-02 BR BRPI0910251A patent/BRPI0910251A2/pt not_active IP Right Cessation
- 2009-03-02 JP JP2010549775A patent/JP2011513414A/ja not_active Ceased
- 2009-03-02 ES ES09721183T patent/ES2399009T3/es active Active
- 2009-03-02 CA CA2717632A patent/CA2717632A1/en not_active Abandoned
- 2009-03-02 AU AU2009223435A patent/AU2009223435B9/en not_active Ceased
- 2009-03-02 DK DK09721183.3T patent/DK2257548T3/da active